Thromboxane A2 and Prostaglandin I2 as Precipitating Factors of Vasospastic and Thrombotic Events in Coronary Artery Disease

  • T. Kuzuya
  • S. Hoshida
  • M. Yamagishi
  • M. Ohmori
  • H. Matsuda
  • M. Tada
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 46)


Recent clinical evidence has indicated that during the active phase of coronary artery disease, coronary thrombosis and/or vasospasm could initiate the pathological events associated with angina pectoris and acute myocardial infarction (1). Platelet aggregates within the coronary circulation may exert their effects directly through machanical obstruction to blood flow, resulting in myocardial ischemic injury. In addition they may release thromboxane A2 (TXA2), a potent vasoconstrictor and platelet aggregating agent (2), thereby causing coronary vasospasm and myocardial ischemia. We have already shown that transcardiac TXA2 release is associated with the induction of myocardial ischemia in patients with angina pectoris (3).


Angina Pectoris Coronary Sinus Anginal Attack Coronary Vasospasm Variant Angina 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Maseri A, Chierchia S: Coronary artery spasm: Demonstration, Definition, Diagnosis, and Consequences. Prog Cardiovasc Dis (25):169–192, 1982.PubMedCrossRefGoogle Scholar
  2. 2.
    Hamberg M, Svensson J, Samuelsson B: Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U.S.A. (72):2994–2998, 1975.PubMedCrossRefGoogle Scholar
  3. 3.
    Tada M, Kuzuya T, Inoue M, Kodama K, Mishima M, Yamada M, Inui M, Abe H: Elevation of thromboxane B2 levels in patients with classic and variant angina pectoris. Circulation (64):1107–1115, 1981.PubMedCrossRefGoogle Scholar
  4. 4.
    Borer JS: Unstable angina: A lethal gun with an invisible trigger. N Engl J Med (302): 1200–1201, 1980.PubMedCrossRefGoogle Scholar
  5. 5.
    Braunwald E: Coronary spasm and acute myocardial infarction-new possibility for treatment and prevention. N Engl J Med (299):1301–1303, 1978.PubMedCrossRefGoogle Scholar
  6. 6.
    Chierchia S, Brunelli C, Simonetti I, Lazzari M, Maseri A: Sequence of events in angina at rest: Primary reduction in coronary flow. Circulation (61):759–768, 1980.PubMedGoogle Scholar
  7. 7.
    Oliva PB, Brenkinridge JC: Arteriographic evidence of coronary arterial spasm in acute myocardial infarction. Circulation (56):366–374, 1977.PubMedGoogle Scholar
  8. 8.
    Moncada S, Gryglewski R, Bunting S, Vane JR: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (263):663–665, 1976.PubMedCrossRefGoogle Scholar
  9. 9.
    Borgeat P, Samuelsson B: Metabolism of arachidonic acid in polymorphonuclear leukocytes. Structural analysis of novel hydroxylated compounds. J Biol Chem (254): 7865–7869, 1979.PubMedGoogle Scholar
  10. 10.
    Sobel M, Salzman EW, Davies GC, Handin RI, Sweeney J, Ploetz J, Kurland G: Circulating platelet products in unstable angina pectoris. Circulation (63): 300–306, 1981.PubMedCrossRefGoogle Scholar
  11. 11.
    De Boer AC, Turpie AGG, Butt RW, Johnston RV, Genton E: Platelet release and thromboxane synthesis in symptomatic coronary artery disease. Circulation (66): 327–333, 1982.PubMedCrossRefGoogle Scholar
  12. 12.
    Kuzuya T, Tada M, Ohmori M, Inui M, Inoue M, Abe H, Yamagishi M, Kodama K: Altered metabolism of thromboxane A2 and prostaglandin I2 in patients with angina pectoris. (abstr) Circulation (64):IV–143, 1981.Google Scholar
  13. 13.
    Lewy RI, Wiener L, Walinsky P, Lefer AM, Silver MJ, Smith JB: Thromboxane release during pacing-induced angina pectoris: possible vasoconstrictor influence on the coronary vasculature. Circulation (61): 1165–1171, 1980.PubMedGoogle Scholar
  14. 14.
    Mehta J, Mehta P, Pepine CJ: Platelet aggregation in aortic and coronary venous blood in patients with and without coronary disease. Circulation (58): 881–886, 1978.PubMedGoogle Scholar
  15. 15.
    Ruf W, McNamara JJ, Suehiro A, Suehiro G, Wickline SA: platelet trapping in myocardial infarct in baboons: Therapeutic effect of aspirin. Am J Cardiol (46):405–412, 1980.PubMedCrossRefGoogle Scholar
  16. 16.
    Gryglewski RJ, Dembinska-Kiec A, Zmuda A, Gryglewska T: Prostacyclin and thromboxane A2 biosynthesis capacities of heart, arteries and platelets at various stages of experimental atherosclerosis in rabbits. Atherosclerosis (31):385–394, 1978.PubMedCrossRefGoogle Scholar
  17. 17.
    Tada M, Esumi K, Yamagishi M, Kuzuya T, Matsuda H, Abe H, Uchida Y, Murao S: Reduction of prostacyclin synthesis as a possible cause of transient flow reduction in a partially constricted canine coronary artery. J Mol Cell Cardiol 1984, in press.Google Scholar
  18. 18.
    Hsueh W, Needleman P: Sites of lipase activation and prostaglandin synthesis in isolated, perfused rabbit hearts and hydronephrotic kidney. Prostaglandins (16):661–681, 1978.CrossRefGoogle Scholar
  19. 19.
    Prinzmetal M, Kennamer R, Merliss R, Wada T, Bor N: Angina pectoris I. A variant form of angina pectoris. Am J Med (27): 375–388, 1959.PubMedCrossRefGoogle Scholar
  20. 20.
    Ohmori M, Tada M, Kuzuya T, Yamagishi M, Matsuda H, Inoue M, Abe H, Kodama K: Thromboxane A2 as a precipitating factor in coronary arterial spasm of variant angina, (abstr) Circulation (68):111–22, 1983.Google Scholar
  21. 21.
    Waters DD, Theroux P, Szlachcic J, Dauwe F: Provocative testing with ergonovine to assess the efficacy of treatment with nifedipine, diltiazem and verapamil in variant angina. Am J Cardiol (48):123–130, 1981.PubMedCrossRefGoogle Scholar
  22. 22.
    Hirsh PD, Campbell WB, Willerson JT, Hillis LD: Prostaglandins and ischemic heart disease. Am J Med (71):1009–1026, 1981.PubMedCrossRefGoogle Scholar
  23. 23.
    Moncada S, Vane JR: Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med (300):1142–1147, 1979.PubMedCrossRefGoogle Scholar
  24. 24.
    Kuzuya T, Tada M, Hoshida S, Ohmori M, Matsuda H, Inoue M, Abe H, Minamino T: Excessive thromboxane A2 generation could be a possible aggravating factor in unstable angina, (abstr) Circulation (68): III–398, 1983.Google Scholar
  25. 25.
    Tada M, Hoshida S, Kuzuya T, Inoue M, Minamino T, Abe H: Augmented thromboxane A2 generation and efficacy of its blockade in acute myocardial infarction. Br Heart J 1984, in press.Google Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1985

Authors and Affiliations

  • T. Kuzuya
    • 1
  • S. Hoshida
    • 1
  • M. Yamagishi
    • 1
  • M. Ohmori
    • 1
  • H. Matsuda
    • 1
  • M. Tada
    • 1
  1. 1.Division of Cardiology, First Department of MedicineOsaka University School of MedicineOsaka 553Japan

Personalised recommendations